Drug Trial Radar · NCT01377922
A Phase 3 Study of Amifampridine Phosphate in Patients With Lambert Eaton Myasthenic Syndrome (LEMS)
Last checked: Nov 20, 2026Latest source record: Jan 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
38
Actual
Start
Jun 2011
Primary completion
Jul 2016
Study completion Jul 2016
Sponsor
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 22, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3 study to evaluate the efficacy and safety of Amifampridine Phosphate in patients with Lambert-Eaton Myasthenic Syndrome (LEMS).
Conditions
- Lambert Eaton Myasthenic Syndrome
Interventions
Amifampridine PhosphateDrug
Amifampridine, 30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets), for 2 weeks.
PlaceboDrug
Matching placebo tablets administered 3-4 times a day (to the individual patient's tablet count of active at baseline) over 2 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline Quantitative Myasthenia Gravis (QMG) at 14 DaysTime frame: Assessment at Baseline and Day 14
- Change in SGI ScoreTime frame: Assessment at Baseline and Day 14
Locations
14 sites in 8 countries. Site status is shown where the registry gives one.
Site not named
Birmingham, Alabama
Site not named
Scottsdale, Arizona
Site not named
Los Angeles, California
Site not named
Palo Alto, California
Site not named
Kansas City, Kansas
Site not named
New York, New York
Site not named
Lyon, France
Site not named
Berlin, Germany
Site not named
Munich, Bavaria, Germany
Site not named
Pécs, Hungary
Site not named
Warsaw, Poland
Site not named
Moscow, Russia
Site not named
Belgrade, Serbia
Site not named
Madrid, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.